Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Nitidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 3/20 | 0.71 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.78 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.78 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.71 |
| ▸ | MAPT | P10636 | 5/20 | 0.71 |
| ▸ | HPGD | P15428 | 5/20 | 0.71 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | RAC1 | P63000 | 4/20 | 0.71 |
| ▸ | BCHE | P06276 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 3/20 | 0.71 |
| ▸ | GMNN | O75496 | 2/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.71 |
| ▸ | BLM | P54132 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.71 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.71 |
| ▸ | BAD | Q92934 | 2/20 | 0.71 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nitidine SCHEMBL31273992 | 1.00 | BCL2L1 (0.78) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Nitidine SCHEMBL164193 | 0.99 | BCL2L1 (0.76) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Nitidine SCHEMBL8014101 | 0.99 | BCL2L1 (0.80) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Nitidine SCHEMBL31539472 | 0.99 | BCL2L1 (0.80) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| SCHEMBL11749304 | 0.91 | BCL2L1 (0.68) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| SCHEMBL13170174 | 0.88 | BCL2L1 (1.00) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| SCHEMBL13839324 | 0.85 | RAD52 (0.81) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Chelerythrine SCHEMBL30207103 | 0.83 | ALDH1A1 (1.00) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Chelerythrine SCHEMBL195109 | 0.83 | ALDH1A1 (1.00) | BCL2L1MCL1BAK1ALDH1A1MAPT | |
| Fagaridine SCHEMBL6961260 | 0.82 | ALDH1A1 (0.78) | BCL2L1MCL1BAK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117209426-B | Nitidine-like sulfonamide derivative and preparation method and application thereof | 广西中医药大学 | 2026-05-19 | — | — | CN | claimed |
| CN-122012371-A | External vesicle from radix zanthoxyli, preparation method and application thereof in preparation of medicine for preventing and treating acute lung injury | 广西壮族自治区人民医院 | 2026-05-12 | — | — | CN | claimed |
| WO-2026086871-A1 | ANTI-AGEING COMPOUNDS, USES THEREFOR, METHOD FOR IDENTIFYING, AND COMPOSITIONS CONTAINING | Centre for Translational Stem Cell Biology Limited (CN) | 2026-04-30 | — | — | WO | claimed |
| CN-120195323-A | Method for detecting pyrrolizidine alkaloids in food | 中国测试技术研究院 | 2025-06-24 | — | — | CN | claimed |
| CN-120052257-A | Method for improving content of nitidine chloride in tissue culture material of radix zanthoxyli and application | 广西壮族自治区药用植物园 | 2025-05-30 | — | — | CN | claimed |
| CN-118948852-B | Cetirizine hydrochloride oral liquid, preparation process and application | 常州市儿童医院(常州市第六人民医院) | 2025-05-27 | — | — | CN | claimed |
| CN-119569966-A | Preparation method and application of rosin-based chloridized nitine molecularly imprinted polymer | 广西民族大学 | 2025-03-07 | — | — | CN | claimed |
| CN-119464210-A | DC cell culture medium and preparation method thereof | 丽山健康(山东)集团有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-118948852-A | Cetirizine hydrochloride oral liquid, preparation process and application | 常州市儿童医院(常州市第六人民医院) | 2024-11-15 | — | — | CN | claimed |
| CN-116375721-B | Photooxidation in-situ generation nitidine and application thereof in preparation of cell probes and anticancer drugs | 佛山大学 | 2024-11-15 | — | — | CN | claimed |
| US-20050266105-A1 | Compositions comprising natural agents for the treatment of HIV-associated opportunistic infections and complications and methods for preparing and using compositions comprising natural agents | ASHIAGBOR KWAME T | 2005-12-01 | — | — | US | claimed |
| US-20050187240-A1 | Aaptamine and isoaaptamine and structural modifications thereof | THE ARIZONA BOARD OF REGENTS, ACTING FOR AND ON BEHALF OF THE ARIZONA STATE UNIVERSITY | 2005-08-25 | — | — | US | claimed |
| US-20050187172-A1 | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia | PFIZER INC. | 2005-08-25 | — | — | US | claimed |
| CN-1568166-A | Coated stent for preventing restenosis | HEMOTEQ GMBH (DE) | 2005-01-19 | — | — | CN | claimed |
| EP-1307197-A2 | COMPOSITIONS FOR THE TREATMENT OF CANCER COMPRISING A TOPOISOMERASE INHIBITOR AND THALIDOMIDE | CELGENE CORPORATION (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020035090-A1 | Compositions and methods for the treatment of cancer | CELGENE CORPORATION | 2002-03-21 | — | — | US | claimed |
| WO-2001087307-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | CELGENE CORP. (US) | 2001-11-22 | — | — | WO | claimed |
| CN-1191130-A | Anti-AIDS virus, anti-Treponema pallidum, anti-gonococcus, anti-candida albicans and anti-trichomonas natural drug | LEI XUEJUN (CN) | 1998-08-26 | — | — | CN | claimed |
| CN-1189365-A | Medicine for preventing Aids virus, treponema pallidum, neisseria gonorrhoeae and trichomonad | LEI XUEJUN (CN) | 1998-08-05 | — | — | CN | claimed |
| CN-1124653-A | Natural medicine for resisting pyloric Helicobacterium | LEI XUEJUN (CN) | 1996-06-19 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050266105-A1 | Compositions comprising natural agents for the treatment of HIV-associated opportunistic infections and complications and methods for preparing and using compositions comprising natural agents | ZAP70, LSS, ITGAM | ACHE 243/4885BCL2L1 1919/4885MCL1 835/4885 |
| US-20050187240-A1 | Aaptamine and isoaaptamine and structural modifications thereof | HNMT, INMT, PNMT | ACHE 1138/4885BCL2L1 3576/4885MCL1 1091/4885 |
| US-20050187172-A1 | Combination of a Cox-2 inhibitor and a DNA topoisomerase I inhibitor for treatment of neoplasia | TOP2A, TOP2B, TOP1 | ACHE 3864/4885BCL2L1 562/4885MCL1 596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.